Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder-Reference-Cited by-同舟云学术

Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder

Published:2012-09 Issue:9 Volume:26 Page:733-759
ISSN:1172-7047
Container-title:CNS Drugs
language:en
Short-container-title:CNS Drugs

Author:

De Hert Marc,Yu Weiping,Detraux Johan,Sweers Kim,van Winkel Ruud,Correll Christoph U.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Psychiatry and Mental health,Clinical Neurology

Reference78 articles.

1. Past and Present Progress in the Pharmacologic Treatment of Schizophrenia

2. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

3. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice

4. Effectiveness of Medications Used to Attenuate Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-Analysis

Cited by 145 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Lurasidone vs. Quetiapine XR in Acutely Psychotic Patients With Schizophrenia in Korea: A Randomized, Double-Blind, Active-Controlled Trial;Psychiatry Investigation;2024-07-25

2. A review on side effect management of second-generation antipsychotics to treat schizophrenia: a drug safety perspective;Expert Opinion on Drug Safety;2024-05-06

3. Efficacy and safety of lurasidone for schizophrenia: A systematic review and meta‑analysis of eight short‑term, randomized, double‑blind, placebo‑controlled clinical trials;Biomedical Reports;2024-04-11

4. Mental Disorders and Diabetes;Textbook of Diabetes;2024-01-12

5. Drug‐Induced Diabetes;Textbook of Diabetes;2024-01-12